Impact behavior of automotive grade medium manganese steel: Reviews on current progress and challenges
Materials Science and Technology · 21.01.2026
DOI: 10.1177/02670836251412337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Materials Science and Technology, online erschienen am 21.01.2026. Verfasst von Sudipta Mohapatra und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 242 Literaturangaben.
Abstract (Originalsprache)
The purpose of this review is to provide a critical analysis of the impact behavior of automotive grade medium manganese steel (MMnS), with a specific focus on the advancements made in fundamental research. An effective review of works pertaining to the impact behavior of thermomechanically processed MMnS has been executed, with a focus on various factors such as alloying elements, plastic deformation, rolling temperature, heat treatment schedules, and ductile-to-brittle transition temperature. In addition, the future scopes and challenges of MMnS are elucidated in the present work. It is observed that increased annealing temperatures in MMnS result in enhanced impact toughness, attributed to the extended crack length and elevated austenite content.
Zitieren
APA
Mohapatra, S., Sarkar, A., Kumar, S., Dalai, R., & Oh, M. (2026). Impact behavior of automotive grade medium manganese steel: Reviews on current progress and challenges. Materials Science and Technology. https://doi.org/10.1177/02670836251412337
Vancouver
Mohapatra S, Sarkar A, Kumar S, Dalai R, Oh M. Impact behavior of automotive grade medium manganese steel: Reviews on current progress and challenges. Materials Science and Technology. 2026. doi:10.1177/02670836251412337
BibTeX
@article{Mohapatra2026,
author = {Mohapatra, Sudipta and Sarkar, Arnab and Kumar, Suman and Dalai, Renuprava and Oh, Min-Suk},
title = {Impact behavior of automotive grade medium manganese steel: Reviews on current progress and challenges},
journal = {Materials Science and Technology},
year = {2026},
doi = {10.1177/02670836251412337}
}
EUVIMED